Abstract
Abstract:A 65-year-old female patient with glioblastoma multiforme (GBM) developed aplastic anemia following treatment with temozolomide. Following her diagnosis of GBM, the patient received standard treatment with surgery, concomitant radiation therapy and temozolomide followed by adjuvant temozolomide. On day 14 of her adjuvant treatment, she developed profound fatigue and spontaneous bruising and was noted to be severely pancytopenic. After an extensive workup, she was found to have aplastic anemia on bone marrow bipsy. Further studies did not reveal any other etiology and she was not on any other medications known to cause aplastic anemia. There have been two previously published cases involving aplastic anemia due to temozolomide. This case represents a rare but potentially fatal toxicity from temozolomide.
This content is limited to qualifying members.
If you have an existing account please login now to access this article or view purchase options.
Create a free account, then purchase this article to download or access it online for 24 hours.
Create a free account, then purchase a subscription to get complete access to all articles for a full year.
References
References1.Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352:987–996.StuppR]]MasonWP]]van den BentMJ&etal;Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.N Engl J Med2005352987-9962.Singhal N, Selva-Nayagam S, Brown MP. Prolonged and severe myelosuppression in two patients after low-dose temozolomide treatment—case study and review of literature. J Neurooncol 2007;85:229–230.SinghalN]]Selva-NayagamS]]BrownMPProlonged and severe myelosuppression in two patients after low-dose temozolomide treatment—case study and review of literature.J Neurooncol200785229-2303.Jalali R, Singh P, Menon H, et al. Unexpected case of aplastic anemia in a patient with glioblastoma multiforme treated with Temozolomide. J Neurooncol 2007;85:105–107.JalaliR]]SinghP]]MenonH&etal;Unexpected case of aplastic anemia in a patient with glioblastoma multiforme treated with Temozolomide.J Neurooncol200785105-1074.Villano JL, Collins CA, Mansanch EE, et al. Aplastic anaemia in patient with glioblastoma multiforme treated with temozolomide. Lancet Oncol 2006;7:436–438.VillanoJL]]CollinsCA]]MansanchEE&etal;Aplastic anaemia in patient with glioblastoma multiforme treated with temozolomide.Lancet Oncol20067436-4385.Young NS, Calado RT, Scheinberg P. Current concepts in the pathophysiology and treatment of aplastic anemia. Blood 2006;108:2509–2519.YoungNS]]CaladoRT]]ScheinbergPCurrent concepts in the pathophysiology and treatment of aplastic anemia.Blood20061082509-25196.Kaufman DW, Kelly JP, Levy M, et al. The Drug Etiology of Agranulocytosis and Aplastic Anemia. New York, Oxford University Press, 1991.KaufmanDW]]KellyJP]]LevyM&etal;The Drug Etiology of Agranulocytosis and Aplastic Anemia.New YorkOxford University Press19917.Young NS. Acquired aplastic anemia. Ann Intern Med 2002;136:534–546.YoungNSAcquired aplastic anemia.Ann Intern Med2002136534-5468.Levy A, Guitera P, Kerob D, et al. Hypersensitivity to dacarbazine in patients with metastatic malignant melanoma. Ann Dermatol Venereol 2006;133:157–160.LevyA]]GuiteraP]]KerobD&etal;Hypersensitivity to dacarbazine in patients with metastatic malignant melanoma.Ann Dermatol Venereol2006133157-1609.Young NS, Scheinberg P, Calado RT. Aplastic anemia. Curr Opin Hematol 2008;15:162–168.YoungNS]]ScheinbergP]]CaladoRTAplastic anemia.Curr Opin Hematol200815162-16810.Horowitz MM. Current status of allogeneic bone marrow transplant in acquired aplastic anemia. Semin Hematol 2000;37:30–42.HorowitzMMCurrent status of allogeneic bone marrow transplant in acquired aplastic anemia.Semin Hematol20003730-4211.FDA Drug Safety Newsletter. Vol 1 (1), Fall 2007.
